CDRD, Canada’s national Centre for Drug Research and Development, is a global bridge that translates discoveries into innovative therapeutic products & improved health outcomes. In collaboration with our partners, we identify & advance promising discoveries & transform them into validated investments – all while uniquely training the next generation of highly-qualified personnel to drive the development of the innovations of tomorrow.
Scroll down to find out how we do this...
Identify & Evaluate
We proactively identify and evaluate
therapeutically promising and commercially relevant early-stage technologies within academia and Canadian life sciences companies.
Validate & Incubate
We replicate data, and build interdisciplinary
teams of experts to define and execute critical
experiments that will maximize probability of future clinical success and attract capital.
Accelerate & Commercialize
We generate valuable data around a technology, build a compelling business case and
comprehensive intellectual property package, and secure the private sector investors / partners to take the technology to patients.
Zymeworks Advances Clinical Candidate Incorporating Technology Developed by CDRD Spin-Off Company Kairos TherapeuticsMarch 15, 2018
CDRD, Canada’s national drug development and commercialization centre, is pleased to share that “ZW49” by Zymeworks is the first product candidate selected for clinical development utilizing the ZymeLink™ antibody-drug conjugate (ADC) platform, acquired as part of the Company’s 2016 acquisition of Kairos Therapeutics. ZW49 was developed...Budget 2018: A Platform for Scale and Focus in Canadian...Read More
March 5, 2018
Canadian life sciences can lead the world – but we’re not there yet. The good news is we now have many of the tools to get there....CDRD Announces Appointments to its Board of DirectorsRead MoreZymeworks Advances Clinical Candidate Incorporating...Read More
February 6, 2018
Today CDRD announced the appointment of Dr. Brad Popovich as Chair of its Board of Directors, Mr. Douglas Wilkes as Vice-Chair, and Dr. Laurence Rulleau as a new Director of the organization....CDRD Appoints Dr. Rachael Ritchie Vice President, Strategy...Read MoreBudget 2018: A Platform for Scale and Focus in Canadian...Read More
November 16, 2017
As a developer and manager of large-scale, multi-partner, strategic partnerships, and interdisciplinary teams and projects, Dr. Ritchie will be responsible for the development and execution of CDRD’s corporate strategy, external R&D alliances, strategic scientific guidance for CDRD’s project portfolio, and will assume management responsibility for CDRD’s...Merck & CDRD Announce Joint Investment in the Canadian...Read MoreCDRD Announces Appointments to its Board of DirectorsRead More
November 3, 2017
Merck & CDRD announced the establishment of a new $1.5M Merck-CDRD Innovation Fund. This fund will go directly towards the advancement of projects of high therapeutic potential carried out at CDRD in collaboration with academic researchers....Top global translational science organizations to catalyze...Read MoreCDRD Appoints Dr. Rachael Ritchie Vice President, Strategy...Read More
Top global translational science organizations to catalyze translational innovation through new initiative – Translation TogetherSeptember 25, 2017
Five of the world’s top translational science organizations representing the European Union, the United Kingdom, the United States, Canada, and Australia have joined forces under the new banner of Translation Together. This new collaboration will enable the leveraging of complementary scientific and operational strengths of member...CDRD Launches New Video Series Featuring Tomorrow’s...Read MoreMerck & CDRD Announce Joint Investment in the Canadian...Read More
September 24, 2017
A key part of CDRD’s Mission is training the next generation of highly-qualified personnel to drive the development of new innovations. Visit our YouTube Channel to meet some of the impressive young CDRD scientists poised to take on that role....Sepset Biosciences Initiates Multicenter Human Clinical...Read MoreTop global translational science organizations to catalyze...Read More
September 13, 2017
Sepset's initiation of a clinical study is a significant step forward in commercializing a test for health care professionals so they can rapidly and appropriately treat a condition where minutes are the difference between life and death. Current methods to diagnose sepsis take more than 24...LifeArc, Dstl & CDRD Collaborate to Identify...Read MoreCDRD Launches New Video Series Featuring Tomorrow’s...Read More
June 27, 2017
This new collaboration will take a more holistic approach, looking at commonality across pathogens to identify which genes or “targets” express proteins that lead to the production of multi-drug resistant bacteria, and are therefore the most promising from a biophysical and drug discovery based perspective....Aequus Pharmaceuticals & CDRD Announce Research...Read MoreSepset Biosciences Initiates Multicenter Human Clinical...Read More
Aequus Pharmaceuticals & CDRD Announce Research Collaboration to Improve Cannabinoid-based TherapeuticsJune 1, 2017
This initial project leverages CDRD’s expertise in pre-clinical development & target validation for new products, & demonstrates CDRD’s ongoing engagement with life sciences companies in the Canadian marketplace. Products advanced through the collaboration will be commercialized by Aequus....LifeArc, Dstl & CDRD Collaborate to Identify...Read More
Zucara received funding that will enable the company to conduct critical validation work and further advance its lead drug candidate ZT-01...Read the article
An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement between Cancer Research UK...Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Novel therapies advancedRead More
August 24, 2017
CDRD has advanced 58 potential novel drug therapies towards the clinic. Many more are in production....Commercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Spin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Commercial transactionsRead More
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources to that typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.